People with schizophrenia experience impaired contrast perception, affecting their ability to differentiate light intensity and recognize shapes and textures.

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on artificial ...

Alto Neuroscience , Inc. (NYSE:ANRO), a pharmaceutical company currently trading at $4.18 per share, has entered into a Sales Agreement with Leerink Partners LLC, initiating an "at the market" ...

A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics, including a drug for schizophrenia.

The proportion of new cases of schizophrenia associated with a cannabis use disorder has risen from 4% pre-legalization to 10 ...

Scientists at Stanford Medicine are advancing the understanding of schizophrenia by creating a "periodic table" for ...

After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...

Boehringer Ingelheim’s investigational schizophrenia candidate has failed ... s $16.5 billion Catalent buy in February 2024—Alto Neuroscience founder and CEO Amit Etkin, M.D., Ph.D., argued ...

JPM24: After 'clearing the decks,' Alkermes ready to roll as pure-play neuroscience company Alkermes also has high hopes for schizophrenia and bipolar combo drug Lybalvi, the selling point of ...